Charles Crow on LinkedIn: Prevagen®: Analysis of Clinical Evidence and Its Designation as a "#1… (2024)

AU / UA It is amazing how many Auburn people will say ROOOOOLLLLL Tide - but how slow they Bama folks are to say War Eagle

3 Comments

Retatrutide

Retatrutide Move over, Mounjaro: New Eli Lilly drug lost patients 24 percent of their weight in trialsA new Eli Lilly experimental drug has helped patients lose 24 percent of their weight, according to new mid-stage clinical trial results. The results,released Monday, followed 338 adults, nearly 52 percent of whom were men, who were obese or overweight and had either received Eli Lilly’s retatrutide injection or a placebo treatment. Retatrutide is a weekly injection that changes the way patients eat, mimicking certain hormones in the gut and leading to the patient having a decreased appetite,according toCNBC. Retatrutide is comparable to Eli Lilly’s other obesity drug, Mounjaro.Mounjaro, which can also be used for Type 2 diabetes treatment, helped patients lose 21 percent of their body weight in a clinical trial, CNBC reported. The phase two trial saw patients who took a 12-milligram dose of retatrutide lose 17.5 percent of their weight after 24 weeks, compared with patients who lost 1.6 percent of their body weight in the placebo group. After 48 weeks, patients using retatrutide lost 24.2 percent of their body fat, and those who took a placebo lost 2.1 percent of their body weight.In their conclusion, the trial researchers said that retatrutide treatment resulted in substantial reductions in body weight for those who took the medication. riple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialAbstractRetatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 weeks in participants from that study with metabolic dysfunction-associated steatotic liver disease and ≥10% of LF. Here, in this randomized, double-blind, placebo-controlled trial, participants (n = 98) were randomly assigned to 48 weeks of once-weekly subcutaneous retatrutide (1, 4, 8 or 12 mg dose) or placebo. The mean relative change from baseline in LF at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) and +0.3% (placebo) (allP < 0.001 versus placebo). At 24 weeks, normal LF (<5%) was achieved by 27% (1 mg), 52% (4 mg), 79% (8 mg), 86% (12 mg) and 0% (placebo) of participants. LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism.

3 Comments

GIP and GLP-1, the two incretin hormones: Similarities and differences Yutaka Seino1,Mitsuo f*ckushima2,Daisuke Yabe1 Affiliationsexpand PMID:24843404PMCID:PMC4020673DOI:10.1111/j.2040-1124.2010.00022.x Abstract Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two primary incretin hormones secreted from the intestine on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. GIP and GLP-1 exert their effects by binding to their specific receptors, the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), which belong to the G-protein coupled receptor family. Receptor binding activates and increases the level of intracellular cyclic adenosine monophosphate in pancreatic β cells, thereby stimulating insulin secretion glucose-dependently. In addition to their insulinotropic effects, GIP and GLP-1 play critical roles in various biological processes in different tissues and organs that express GIPR and GLP-1R, including the pancreas, fat, bone and the brain. Within the pancreas, GIP and GLP-1 together promote β cell proliferation and inhibit apoptosis, thereby expanding pancreatic β cell mass, while GIP enhances postprandial glucagon response and GLP-1 suppresses it. In adipose tissues, GIP but not GLP-1 facilitates fat deposition. In bone, GIP promotes bone formation while GLP-1 inhibits bone absorption. In the brain, both GIP and GLP-1 are thought to be involved in memory formation as well as the control of appetite. In addition to these differences, secretion of GIP and GLP-1 and their insulinotropic effects on β cells have been shown to differ in patients with type 2 diabetes compared to healthy subjects. We summarize here the similarities and differences of these two incretin hormones in secretion and metabolism, their insulinotropic action on pancreatic β cells, and their non-insulinotropic effects, and discuss their potential in treatment of type 2 diabetes. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00022.x, 2010).Activate to view larger image,

1 Comment

A Tree and its Fruit…21Not everyone who says to Me, ‘Lord, Lord,’ will enter the kingdom of heaven, but only he who does the will of My Father in heaven.22Manywill sayto Meonthatday,‘Lord,Lord,did we not prophesyinYourname,andinYournamedrive outdemonsandperformmanymiracles?’23Then I will tell them plainly, ‘I never knew you; depart from Me, you workers of lawlessness!’…

Some of the deconversion from Christianity - the question could be - if you are not disciplined by the Lord for the way you live your life - were you ever converted The Lord disciples the ones He loves

this is before moujario 220 lbs after 198 lbs https://lnkd.in/e__Rq6na

Diabetics - I would look at yogurt with lacto bacillus and almonds to increase GLP-1 and lower BS

berberine endothelium

stronger rats A Phytomolecule Icariin Protects from Sarcopenia Partially by Suppressing Myosin Heavy Chain Degradation in Orchiectomized RatsWen-Yao Yang12,Hui-Juan Cao12,Ling Li12,Cui-Shan Huang12,Ke-da Shi1,Antonia Ru-Jia Sun13,Ling Qin124,Xin-Luan Wang12AffiliationsexpandPMID:36026561DOI:10.1002/adbi.202200162AbstractTreatments are lacking for sarcopenia, which is an age-related disease characterized by loss of skeletal muscle mass, strength, and/or physical performance. Icariin is a phytomolecule from herbal Epimedium, a traditional Chinese medicine widely used to treat musculoskeletal disorders for thousands of years. Here the effects of icariin against sarcopenia are investigated and the underlying mechanism is elucidated. A classic rat model of bilaterally orchiectomized (ORX) is used to induce sarcopenia. After administration for 8 weeks, compared to the control group, the forelimb grip strength, the specific tetanic forces of the soleus (SOL) and extensor digitorum longus muscle (EDL) are higher, and the fiber cross-sectional areas (CSAs) of the gastrocnemius and tibialis anterior muscle are larger in the icariin group. In addition, icariin promotes mRNA and protein expressions of myosin heavy chain (MyHC) both in SOL and EDL. Mechanistically, icariin significantly suppresses the mRNA and protein expressions of FOXO3a, atrogin-1, and MuRF-1, which are related to the degradation of myosin heavy chain. Collectively, icariin protects from sarcopenia in ORX rats characterized by enhancing grip strength and skeletal muscle contraction, as well as increasing skeletal muscle CSA by inhibiting the ubiquitination degradation of the MyHC in skeletal muscle fibers.